Evidence map›Paper›PMID 40244855›Full record

ArticleSTAR protocols2025

Protocol for mpox virus inactivation in containment level 3 for safe handling of animal samples.

Benedicte Mpia Moni, Arianna Mahely Hurtado-Monzón, Jill Van Kessel, Robert A Kozak, Antonio Facciuolo, Arinjay Banerjee, Anil Kumar

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in STAR protocols, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Benedicte Mpia MoniVaccine and Infectious Disease Organization (VIDO), University of Saskatchewan, Saskatoon, SK S7N 5E3, Canada; Department of Virology, National Institute for Biomedical Research, Kinshasa, DR Congo; Department of Biology, Faculty of Science and Technology, BP 190 Kinshasa XI, University of Kinshasa, Kinshasa, DR Congo; School of Medicine, Catholic University of Congo, Kinshasa, DR Congo.
Arianna Mahely Hurtado-MonzónVaccine and Infectious Disease Organization (VIDO), University of Saskatchewan, Saskatoon, SK S7N 5E3, Canada.
Jill Van KesselVaccine and Infectious Disease Organization (VIDO), University of Saskatchewan, Saskatoon, SK S7N 5E3, Canada.
Robert A KozakSunnybrook Research Institute, Toronto, ON M4N 3M5, Canada.
Antonio FacciuoloVaccine and Infectious Disease Organization (VIDO), University of Saskatchewan, Saskatoon, SK S7N 5E3, Canada; Department of Veterinary Microbiology, Western College of Veterinary Medicine, University of Saskatchewan, Saskatoon, SK S7N 5B4, Canada. Electronic address: antonio.facciuolo@usask.ca.
Arinjay BanerjeeVaccine and Infectious Disease Organization (VIDO), University of Saskatchewan, Saskatoon, SK S7N 5E3, Canada; Department of Veterinary Microbiology, Western College of Veterinary Medicine, University of Saskatchewan, Saskatoon, SK S7N 5B4, Canada; Department of Biology, University of Waterloo, Waterloo, ON, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada; Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, BC, Canada. Electronic address: arinjay.banerjee@usask.ca.
Anil KumarDepartment of Biochemistry, Microbiology and Immunology, College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada. Electronic address: anil.kumar@usask.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High biocontainment is required to handle infectious mpox virus (MPXV) specimens, which can hinder research and diagnostic efforts during outbreaks. Here, we present a protocol for inactivating MPXV-contaminated animal samples using commercial lysis buffers. We describe steps for virus propagation and quantification and MPXV inactivation. We then detail procedures for validating the inactivation using a cell-based technique and qPCR. This protocol provides a framework for safely managing MPXV in lower-containment laboratories, facilitating downstream applications and improved outbreak management.

Indexed as

Containment of BiohazardsMonkeypox virusMpox, MonkeypoxSpecimen HandlingVirus InactivationAnimalsCell cultureMicrobiologyMolecular Biology

Identifiers

PMID40244855
PMCPMC12224877

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.